¿Importa la secuencia de tratamiento en egfr +?: Factores que deberían ser considerados

Selecting the optimal sequential strategy

First generation

(erlotinib, gefitinib)

or second generation

(afatinib, dacomitinib)

Third generation

Osimertinib

NSCLC

(Stage IV)

EGFR mutation

1. Optimal sequence after progression to TKI

2. Increase in surrogate PFS or Overall Survival

3. Impact on CNS disease metastasis

4. Improvements on QoL

5. Toxicity Profile